middle.news
PYC Therapeutics Advances PYC-001 to Multiple Dose Study for Blinding Eye Disease ADOA
11:12am on Wednesday 15th of April, 2026 AEST
•
Biotechnology
Read Story
PYC Therapeutics Advances PYC-001 to Multiple Dose Study for Blinding Eye Disease ADOA
11:12am on Wednesday 15th of April, 2026 AEST
Key Points
Safety Review Committee approves 60 microgram dose for multiple ascending dose study
Phase 1/2 trial to assess repeated dosing safety and efficacy in ADOA patients
Data readouts expected throughout 2026 and 2027
Progression supports global registrational trial plans
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
PYC Therapeutics (ASX:PYC)
OPEN ARTICLE